Product/Composition:- | Sitagliptin + Metformin XR Tablets |
---|---|
Strength:- | 100/1000 mg |
Form:- | Tablets |
Reference Brands:- | Janumet XR (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sitagliptin inhibits DPP-4, prolonging incretin activity to enhance insulin secretion and suppress glucagon release. Metformin decreases hepatic glucose production and improves insulin sensitivity. The XR formulation ensures steady glucose control with reduced gastrointestinal side effects. Together, they offer synergistic action, improved glycemic control, and convenient once-daily dosing for Type 2 diabetes management.
Sitagliptin + Metformin XR tablets, approved by the FDA (USA) and regulated by the EMA (EU), are indicated for the management of Type 2 diabetes when monotherapy fails. Brands like Janumet XR offer extended glycemic control with once-daily dosing. These tablets must meet stringent bioequivalence, GMP, and pharmacovigilance standards in both markets. EU guidelines require SmPC-compliant labeling and risk management plans. The combination enhances patient adherence and reduces glucose levels effectively. Pharmatradz.com, a global B2B pharmaceutical marketplace, connects buyers with trusted USFDA and EU-GMP certified manufacturers for bulk procurement of Sitagliptin + Metformin XR and other diabetes treatments.